Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia

American Journal Geriatric Pharmacotherapy

Volumn 8, Issue 2, 2010, Pages 98-114

  Muramatsu, Russ S ^a   Litzinger, Mark H J ^b   Ed Fisher, ^c   Takeshita, Junji ^d  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c UNIVERSITY OF HAWAII AT HILO   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

Alternative medication formulations; BPSD; Medication delivery; Psychotropic medicine use in elderly

Indexed keywords

PSYCHOTROPIC AGENT;

AGE; AGED; DEMENTIA; DRUG DELIVERY SYSTEM; HUMAN; OFF LABEL DRUG USE; PSYCHOLOGICAL ASPECT; REVIEW;

AGE FACTORS; AGED; DEMENTIA; DRUG DELIVERY SYSTEMS; HUMANS; OFF-LABEL USE; PSYCHOTROPIC DRUGS;

EID: 77954941091     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2010.03.003     Document Type: Review

References (84)

1. Ames D, ed. International Psychogeriatric Association. Behavioral and psychological symptoms of dementia (BPSD): A clinical and research update. Int Psychogeriatr. 2000;12(Suppl 1):1- 424.
2. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA. 2002;288:1475-1483.
3. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090-2097.
4. Buhr GT, Kuchibhatla M, Clipp EC. Caregivers' reasons for nursing home placement: Clues for improving discussion with families prior to the transition. Gerontologist. 2006;46:52-61.
5. Lebowitz BD. Behavioral and psychological symptoms of dementia (BPSD): A clinical and research update. Int Psychogeriatr. 2000;12(Suppl 1):19-21.
6. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000;15(Suppl 1):S2-S4.
7. Schneider LS, Tariot PN, Dagerman KS, et al, for the CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538.
8. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957-970.
9. Salzman C, Jeste D, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898.
10. Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: Drug development strategies. Nat Rev Drug Discov. 2006;5:64-74.
11. Sultzer DL, Davis SM, Tariot PN, et al, for the CATIEAD Study Group. Clinical symptom responses to atypical antipsychotic medication in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844-854.
12. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164: 1568-1576, quiz 1623.
13. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2008;23:909-914.
14. Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661-666.
15. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
16. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
17. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942-952.
18. Stubbs J, Haw C, Dickens G. Dose form modification-a common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr. 2008;20:616-627.
19. Wright D. Medication administration in nursing homes. Nurs Stand. 2002;16:33-38.
20. Treloar A, Beats B, Philpot M. A pill in the sandwich: Covert medication in food and drink. J R Soc Med. 2000; 93:408-411.
21. Altamura AC, Mauri MC, Girardi T, Panetta B. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. Int J Clin Pharmacol Res. 1990;10:223-228.
22. Finkel SI. Psychotherapeutic agents in older adults. Antipsychotics: Old and new. Clin Geriatr Med. 1998;14: 87-100.
23. Forester B, Vanelli M, Hyde J, et al. Report on an openlabel prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Am J Geriatr Pharmacother. 2007;5:209-217.
24. Laks J, Engelhardt E, Marinho V, et al. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr. 2001; 59:859-864.
25. Lasser RA, Bossie CA, Zhu Y. Efficacy and safety of longacting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004;19:898-905.
26. Nelson JC, Hollander SB, Betzel J, Smolen P, for the Mirtazapine Nursing Home Study Group. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int J Geriatr Psychiatry. 2006;21:898-901.
27. Reeves RR, Torres RA. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. South Med J. 2003;96: 699-701.
28. Yumru M, Eren Ozen M, Savas HA, Selek S. Long-acting injectable risperidone for control of agitation in dementia. J Clin Psychiatry. 2006;67:1651-1652.
29. Geller JL, Gaulin BD, Barreira PJ. A practitioner's guide to use of psychotropic medication in liquid form. Hosp Community Psychiatry. 1992;43:969-971.
30. Thompson D, DiMartini A. Nonenteral routes of administration for psychiatric medications. A literature review. Psychosomatics. 1999;40:185-192.
31. Mler MJ. Attitudes toward different formulations of psychotropic drugs: The view of patients and healthcare providers. Am J Drug Deliv. 2006;4:33-41.
32. Geodon [package insert]. New York, NY: Pfizer Inc; 2008.
33. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2008.
34. Risperdal [package insert]. Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals, Inc; 2009.
35. Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co Ltd; 2009.
36. Invega Sustenna [package insert]. Titusville, NJ: Ortho- McNeil-Janssen Pharmaceuticals, Inc; 2009.
37. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0. Wolters Kluwer Health, Inc. http://www.facts andcomparisons.com/. Accessed January 2, 2009.
38. Lexi-Comp Online. Lexi-Drugs Online. Hudson, Ohio: Lexi-Comp, Inc; 2007. http://online.lexi.com/crlsql/servlet/crlonline. Accessed January 2, 2009.
39. Aki H, Ohta M, Fukusumi K, Okamoto Y. Evaluation of compatibility of risperidone with soft drinks and interactions of risperidone with tea tannin using isothermal titration microcalimetry. Jap J Pharmaceut Health Care Sci. 2006;32:190-198.
40. Trissel LA. Trissel's Stability of Compounded Formulations. 4th ed. Washington, DC: American Pharmacists Association; 2009.
41. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494-504.
42. Barak Y, Mazeh D, Plopski I, Baruch Y. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2006;14:629-633.
43. Viukari M, Salo H, Lamminsivu U, Gordin A. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatr Scand. 1982;65:301-308.
44. Raskind M, Alvarez C, Herlin S. Fluphenazine enanthate in the outpatient treatment of late paraphrenia. J Am Geriatr Soc. 1979;27:459-463.
45. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs. 2003;63:493-512.
46. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983; 309:410-416.
47. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:996-1008.
48. Fraser GL, Prato BS, Riker RR, et al. Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU. Pharmacotherapy. 2000;20:75-82.
49. Regenold WT, Prasad M. Uses of intravenous valproate in geriatric psychiatry. Am J Geriatr Psychiatry. 2001;9: 306-308.
50. Moukaddam NJ, Hirschfeld RM. Intravenous antidepressants: A review. Depress Anxiety. 2004;19:1-9.
51. Yan J. FDA warns of serious side effects from I.V. haloperidol. Psychiatr News. 2007;42:14.
52. Tsai C, Puzantian T. Liquid risperidone in the treatment of psychotic agitation. CNS Drugs. 2002;16:777, author reply 778.
53. Gibson P, Mountjoy CQ, Sutcliffe RL. Palatability of liquid major tranquilizers. Int J Geriatr Psychiatry. 1991; 6:235-238.
54. Chan AL, Chien YW, Jin Lin S. Transdermal delivery of treatment for Alzheimer's disease: Development, clinical performance and future prospects. Drugs Aging. 2008; 25:761-775.
55. Baghai TC, Eser D, Schule C, et al. Selegiline transdermal system in the treatment of depressive disorders. Future Neurol. 2007;2:601-611.
56. Saphris [package insert]. Kenilworth, NJ: Schering Corporation; 2009.
57. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage. 1996;11:378-387.
58. Dooley JM. Rectal use of benzodiazepines. Epilepsia. 1998;39:S24-S27.
59. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage. 1996;11:378-387.
60. Koelle JS, Dimsdale JE. Antidepressants for the virtually eviscerated patient: Options instead of oral dosing. Psychosom Med. 1998;60:723-725.
61. Hilty DM, Rodriguez GD, Hales RE. Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1998;10: 365-366.
62. Norman TR, Olver JS. New formulations of existing antidepressants: Advantages in the management of depression. CNS Drugs. 2004;18:505-520.
63. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly. Drugs Aging. 2003;20:1099-1110.
64. Howard R, Levy R. Which factors affect treatment response in late paraphrenia? Int J Geriatr Psychiatry. 1992; 7:667-672.
65. Glazer WM, Kane JM. Depot neuroleptic therapy: An underutilized treatment option. J Clin Psychiatry. 1992; 53:426-433.
66. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005;293:596-608. (Pubitemid 40171242)
67. Paradiso LM, Roughead EE, Gilbert AL, et al. Crushing or altering medications: What's happening in residential aged-care facilities? Australas J Ageing. 2008;21:123-127.
68. James A. The legal and clinical implications of crushing tablet medication. Nurs Times. 2004;100:28-29.
69. Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: Dosage form selection and administration methods. Hosp Pharm. 2004;39:225-237.
70. Estoup M. Approaches and limitations of medication delivery in patients with enteral feeding tubes. Crit Care Nurse. 1994;14:68-72, 77-79, quiz 80-81.
71. Guenter P. Administering medications via feeding tubes: What consultant pharmacists need to know. Consult Pharm. 1999;14.
72. Mitchell JF. Oral dosage forms that should not be crushed: 2000 Update. Hosp Pharm. 2000;35:553-567.
73. Haw C, Stubbs J, Dickens G. An observational study of medication administration errors in old-age psychiatric inpatients. Int J Qual Health Care. 2007;19:210-216.
74. Bressler R. Grapefruit juice and prescription drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics. 2006;61: 12-18.
75. Kirkevold Ø, Engedal K. Concealment of drugs in food and beverages in nursing homes: Cross sectional study. BMJ. 2005;330:20.
76. Kirkevold O, Engedal K. Is covert medication in Norwegian nursing homes still a problem? A cross-sectional study. Drugs Aging. 2009;26:333-344.
77. Wright D, Chapman N, Foundling-Miah M, et al. Consensus guideline on the medication management of adults with swallowing difficulties. http://www.swallowing difficulties.com/images/pdf/dysphagia%20full%20 guideline2.pdf. Accessed July 1, 2009.
78. Williams NT. Medication administration through enteral feeding tubes. Am J Health-Syst Pharm. 2008;65:2347-2357.
79. Heineck I, Bueno D, Heydrich J. Study on the use of drugs in patients with enteral feeding tubes. Pharm World Sci. 2009;31:145-148.
80. Lamnari AM. Point-Counterpoint: Is it ethical to give drugs to people with dementia? Yes: It is ethical if it is in their best interests. West J Med. 2001;174:228.
81. Treloar A, Philpot M, Beats B. Concealing medication in patients' food. Lancet. 2001;357:62-64.
82. Honkanen L. Point-Counterpoint: Is it ethical to give drugs covertly to people with dementia? No: Covert medication is paternalistic. West J Med. 2001;174:229.
83. Barnes L, Cheek J, Nation RL, et al. Making sure the residents get their tablets: Medication administration in care homes for older people. J Adv Nurs. 2006;56:190-199.
84. Lesar TS. Prescribing errors involving medication dosage forms. J Gen Intern Med. 2002;17:579-587.